2014 Annual Meeting | 2HC.006 - Child Neurology I

Date Sunday 04/27/14

Time 08:00 AM - 12:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Half-Day Course

Director(s) Jonathan W. Mink, MD, PhD, F�鶹��ýӳ��

Topic(s)

Learning Objectives Participants should be able to incorporate newer diagnostic and therapeutic approaches to the management of these categories of neurologic disease occurring in children and adolescents and should be aware of the practice parameters that apply.

CME Available No CME available

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist

Teaching Styles Case-based, Didactic

Event Timeline
08:00 AM - 08:05 AM		Introduction Jonathan W. Mink, MD, PhD, F�鶹��ýӳ��
08:05 AM - 08:50 AM		Tourette Syndrome and Associated Disorders Jonathan W. Mink, MD, PhD, F�鶹��ýӳ��
08:50 AM - 09:00 AM		Questions and Answers Jonathan W. Mink, MD, PhD, F�鶹��ýӳ��
09:00 AM - 09:45 AM		Epileptic Syndromes and Their Treatment Howard P. Goodkin, MD, PhD, F�鶹��ýӳ��
09:45 AM - 09:55 AM		Questions and Answers Howard P. Goodkin, MD, PhD, F�鶹��ýӳ��
09:55 AM - 10:10 AM		Break
10:10 AM - 10:55 AM		Inborn Errors of Metabolism in Child Neurology Marc C. Patterson, MD, FRACP, F�鶹��ýӳ��
10:55 AM - 11:05 AM		Questions and Answers Marc C. Patterson, MD, FRACP, F�鶹��ýӳ��
11:05 AM - 11:50 AM		Neuromuscular Disorders Peter B. Kang, MD, F�鶹��ýӳ��
11:50 AM - 12:00 PM		Questions and Answers Peter B. Kang, MD, F�鶹��ýӳ��

Faculty Disclosures
Jonathan W. Mink, MD, PhD, F�鶹��ýӳ��	The institution of Dr. Mink has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amicus. The institution of Dr. Mink has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurogene. Dr. Mink has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TEVA. Dr. Mink has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapeutics. Dr. Mink has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Applied Therapeutics. Dr. Mink has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for �鶹��ýӳ��. The institution of Dr. Mink has received research support from Neurogene. The institution of Dr. Mink has received research support from NIH. Dr. Mink has received publishing royalties from a publication relating to health care. Dr. Mink has received personal compensation in the range of $500-$4,999 for serving as a Member, Study Section with NINDS.
Howard P. Goodkin, MD, PhD, F�鶹��ýӳ��	Dr. Goodkin has received research support from NIH. Dr. Goodkin has received publishing royalties from a publication relating to health care.
Marc C. Patterson, MD, FRACP, F�鶹��ýӳ��	Dr. Patterson has received personal compensation for serving as an employee of IntraBio. The institution of Dr. Patterson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orphazyme /KemPharm/Zevra. Dr. Patterson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Azafaros. Dr. Patterson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for IntraBio. Dr. Patterson has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Sage. Dr. Patterson has or had stock in IntraBio. The institution of Dr. Patterson has received research support from Glycomine. The institution of Dr. Patterson has received research support from Orphazyme /KemPharm/Zevra. The institution of Dr. Patterson has received research support from Idorsia. The institution of Dr. Patterson has received research support from Shire-Takeda. Dr. Patterson has received publishing royalties from a publication relating to health care. Dr. Patterson has received publishing royalties from a publication relating to health care.
Peter B. Kang, MD, F�鶹��ýӳ��	Dr. Kang has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurogene. Dr. Kang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lupin. Dr. Kang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ITF Therapeutics (Italfarmaco). An immediate family member of Dr. Kang has received personal compensation in the range of $0-$499 for serving as a Consultant for Life Sciences Consultants. Dr. Kang has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MLAB Biosciences. Dr. Kang has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley. Dr. Kang has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for �鶹��ýӳ��. The institution of Dr. Kang has received research support from Xtraordinary Joy Foundation. The institution of an immediate family member of Dr. Kang has received research support from Sarepta Therapeutics. The institution of Dr. Kang has received research support from Centers for Disease Control and Prevention (CDC). The institution of Dr. Kang has received research support from National Institutes of Health (NIH). The institution of Dr. Kang has received research support from Food and Drug Administration. The institution of Dr. Kang has received research support from National Initiative for Cockayne Syndrome. The institution of Dr. Kang has received research support from Greg Marzolf Jr Foundation. The institution of Dr. Kang has received research support from Sarepta Therapeutics. The institution of Dr. Kang has received research support from Duchenne UK - PPMD. The institution of an immediate family member of Dr. Kang has received research support from Regenerative Medicine MN. The institution of an immediate family member of Dr. Kang has received research support from Greg Marzolf Jr Foundation. The institution of an immediate family member of Dr. Kang has received research support from NIH. The institution of an immediate family member of Dr. Kang has received research support from Viljem Julijan Association for Children with Rare Disease. The institution of Dr. Kang has received research support from Minnesota Partnership. Dr. Kang has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Kang has received intellectual property interests from a discovery or technology relating to health care. Dr. Kang has received publishing royalties from a publication relating to health care. Dr. Kang has a non-compensated relationship as a Medical Advisory Board with Speak Foundation that is relevant to �鶹��ýӳ�� interests or activities. Dr. Kang has a non-compensated relationship as a President (Including President-Elect and Past President) with Child Neurology Society that is relevant to �鶹��ýӳ�� interests or activities. Dr. Kang has a non-compensated relationship as a Board Member with Child Neurology Foundation that is relevant to �鶹��ýӳ�� interests or activities.